Arterial thrombosis is a common complication of many systemic diseases, including atherosclerosis, diabetes, cancer, and chronic inflammatory conditions. This proposal will test the hypothesis that CD36 mediates platelet """"""""hyper-reactivity"""""""" associated with systemic diseases, and thus contributes to arterial thrombosis. CD36 is a """"""""pattern recognition"""""""" or scavenger receptor that recognizes ligands such as oxidized LDL, glycated proteins, and apoptotic cell membranes that are generated during pathological conditions. It is thus uniquely positioned to """"""""sense"""""""" disease. Corollaries to the hypothesis are that platelets sensitized by CD36-ligand interactions may be resistant to anti-platelet therapies, and that levels of platelet CD36 expression, perhaps under the influence of genetic polymorphisms, may contribute to human thrombotic risk.
Three specific aims are proposed. The first will utilize in vitro assays of human platelet function to characterize the role of CD36 in platelet activation. Whether CD36 ligands, including oxidized phospholipids, apoptotic cells, advanced glycation end products, and anti-CD36 autoantibodies can sensitize platelets to activation by low concentrations of other agonists will be determined, as will mechanisms by which CD36 initiates platelet signaling cascades.
The second aim will characterize the pro-thrombotic role of CD36 in vivo using murine models. CD36 null mice crossed to an apoE null background will be used as a model of an atherogenic state, and CD36 nulls rendered hyperglycemic will be used as a model of diabetes. The effect of pharmacologic upregulation of CD36 will also be tested.
The third aim will determine the potential role of human CD36 polymorphisms in athero-thrombosis. Variance in levels of human platelet surface CD36 expression among individuals will be correlated with CD36 genotype, and associations of CD36 genotype and platelet CD36 expression with thrombotic risk and platelet resistance to aspirin and/or clopridogel will be determined.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Specialized Center (P50)
Project #
5P50HL081011-04
Application #
7799801
Study Section
Special Emphasis Panel (ZHL1)
Project Start
Project End
Budget Start
2009-03-01
Budget End
2010-02-28
Support Year
4
Fiscal Year
2009
Total Cost
$388,009
Indirect Cost
Name
Cleveland Clinic Lerner
Department
Type
DUNS #
135781701
City
Cleveland
State
OH
Country
United States
Zip Code
44195
Wu, M; Barnard, J; Kundu, S et al. (2015) A novel pathway of cellular activation mediated by antiphospholipid antibody-induced extracellular vesicles. J Thromb Haemost 13:1928-40
Hajj-Ali, Rula A; Major, Jennifer; Langford, Carol et al. (2015) The interface of inflammation and subclinical atherosclerosis in granulomatosis with polyangiitis (Wegener's): a preliminary study. Transl Res 166:366-74
Chaturvedi, Shruti; Cockrell, Erin; Espinola, Ricardo et al. (2015) Circulating microparticles in patients with antiphospholipid antibodies: characterization and associations. Thromb Res 135:102-8
Timur, A Anil; Murugesan, Gurunathan; Zhang, Li et al. (2014) Multi-parameter assessment of platelet inhibition and its stability during aspirin and clopidogrel therapy. Thromb Res 134:96-104
Chaturvedi, Shruti; McCrae, Keith R (2014) Recent advances in the antiphospholipid antibody syndrome. Curr Opin Hematol 21:371-9
Zhao, Y; Xiong, Z; Lechner, E J et al. (2014) Thrombospondin-1 triggers macrophage IL-10 production and promotes resolution of experimental lung injury. Mucosal Immunol 7:440-8
Gupta, Nilaksh; Li, Wei; Willard, Belinda et al. (2014) Proteasome proteolysis supports stimulated platelet function and thrombosis. Arterioscler Thromb Vasc Biol 34:160-8
Li, Wei; Gigante, Alba; Perez-Perez, Maria-Jesus et al. (2014) Thymidine phosphorylase participates in platelet signaling and promotes thrombosis. Circ Res 115:997-1006
Srikanthan, S; Li, W; Silverstein, R L et al. (2014) Exosome poly-ubiquitin inhibits platelet activation, downregulates CD36 and inhibits pro-atherothombotic cellular functions. J Thromb Haemost 12:1906-17
Betapudi, Venkaiah; Lominadze, George; Hsi, Linda et al. (2013) Anti-?2GPI antibodies stimulate endothelial cell microparticle release via a nonmuscle myosin II motor protein-dependent pathway. Blood 122:3808-17

Showing the most recent 10 out of 58 publications